No results for ‘’
Transgene Biotek Ltd
NSE: BSE: 526139
₹2.85
(2.89%)
Tue, 25 Aug 2026, 05:08 pm
Market Cap (in Cr)18.28
PE Ratio0
Dividend0
Health Technology
Biotechnology
24.5KCompany History
1990
- Transgene Biotek Limited was incorporated as a Private Limited Company on 1st March.
- The company was subsequently converted into a Public Limited Company on 28th November.
1993
- The company commenced commercial production.
2011
- The company set up a wholly-owned subsidiary in Hong Kong named Transgene Biotek HK Ltd.
2012
- Transgene readied to launch one of its block-buster drugs - TrabiDHA (DHA) formulations.
2013
- Transgene signed a Joint Venture agreement with Atral Cipan of Portugal involving the technology transfer of Tacrolimus.
- Transgene Biotek became the worldâs first company to create and launch 50% algal DHA oil and 20% algal DHA powder.
2014
- Sri Sarang Subhash Puranik and Shyam Shankar Das were appointed as Directors of the company.